Search
Quinagolide
go.drugbank.com/drugs/DB09097ApprovedWithdrawnHyperprolalctinaemia is associated with gonadal dysfunction, including infertility and reduced libido, as well as long-term complications such as osteoporosis [A19684]. … It is typically present in the hydrochloride salt form and is marketed as oral tablets under the brand name Norprolac contained as a racemate.
Tozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigationalComirnaty is also approved for use as a fourth booster shot in adults 50 years of age and older.[L41350] … The Pfizer-BioNTech COVID-19 vaccine (also known as BNT162b2, Tozinameran, and Comirnaty), is one of four advanced mRNA-based vaccines developed through "Project Lightspeed," a joint program between Pfizer
Esomeprazole
go.drugbank.com/drugs/DB00736ApprovedInvestigational[A177571] Rapid discontinuation of PPIs such as esomeprazole may cause a rebound effect and a short term increase in hypersecretion. … Esomeprazole has been shown to inhibit acid secretion to a similar extent as [DB00338], without any significant differences between the two compounds _in vitro_.
Benzoic acid
go.drugbank.com/drugs/DB03793ApprovedInvestigationalA fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid. … As the sodium salt form, sodium benzoate is used as a treatment for urea cycle disorders due to its ability to bind amino acids.
Atoltivimab
go.drugbank.com/drugs/DB15898ApprovedInvestigational[A222078] INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Atoltivimab (REGN 3470), [Odesivimab] (REGN 3471), and [Maftivimab] (REGN 3479) in equimolar proportions
Besilesomab
go.drugbank.com/drugs/DB13979ApprovedUtilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245159] Pharmacologic strategies have included the targeting of B-cells with agents like [rituximab], as well as targeting of the complement system with drugs like [eculizumab], an anti-C5 mAb, and [ … In addition to non-pharmacological strategies, such as counseling patients to keep warm and the use of red blood cell transfusions, approximately 70% of patients require pharmacological treatment.
Ioxitalamic acid
go.drugbank.com/drugs/DB13444ApprovedWithdrawnIoxitalamate is an ionic iodinated contrast medium. It is a first-generation contrast media formed by an ionic monomer with a high osmolarity of 1500-1800 mOsm/kg. Ioxitalamic acid in the salt forms of sodium and meglumine was developed ...
Sacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigationalAs a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects.
Abaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigationalAbaloparatide is an N-terminal analog of parathyroid hormone-related protein (PTHrP) and an agonist at the parathyroid hormone type 1 (PTH1) receptor. It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone...